ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.

Abstract excerpt

Breast cancer accounts for 25% of the cancers in women worldwide. The most common subtype of breast cancer diagnosed is hormone receptor positive, which expresses the oestrogen receptor (ER). Targeting of the ER with endocrine therapy (ET) is the current standard of care for ER-positive (ER+) breast cancer, reducing the mortality by up to 40%. Resistance to ET, however, remains a major issue for ER + breast...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Neoplasms
• Share to Drug Resistance, Neoplasm
• Share to Estrogen Receptor alpha